脂肪肉瘤
辐射敏感性
肉瘤
滑膜肉瘤
纤维肉瘤
放射治疗
克隆形成试验
病理
软组织肉瘤
平滑肌肉瘤
细胞培养
癌症研究
生物
医学
核医学
内科学
遗传学
作者
Rick L. Haas,B.G.J. Floot,Astrid N. Scholten,Winette T.A. van der Graaf,Winan J. van Houdt,Yvonne Schrage,Marieke van de Ven,Judith V.M.G. Bovée,Frits van Coevorden,Conchita Vens
出处
期刊:Radiation Research
[Radiation Research Society]
日期:2021-04-29
卷期号:196 (1): 23-30
被引量:77
标识
DOI:10.1667/rade-20-00226.1
摘要
Currently, all soft tissue sarcomas (STS) are irradiated by the same regimen, disregarding possible subtype-specific radiosensitivities. To gain further insight, cellular radiosensitivity was investigated in a panel of sarcoma cell lines. Fourteen sarcoma cell lines, derived from synovial sarcoma, leiomyosarcoma, fibrosarcoma and liposarcoma origin, were submitted to clonogenic survival assays. Cells were irradiated with single doses from 1-8 Gy and surviving fraction (SF) was calculated from the resulting response data. Alpha/beta (α/β) ratios were inferred from radiation-response curves using the linear-quadratic (LQ)-model. Cellular radiosensitivities varied largely in this panel, indicating a considerable degree of heterogeneity. Surviving fraction after 2 Gy (SF2) ranged from 0.27 to 0.76 with evidence of a particular radiosensitive phenotype in only few cell lines. D37% on the mean data was 3.4 Gy and the median SF2 was 0.52. The median α/β was 4.9 Gy and in six cell lines the α/β was below 4 Gy. A fairly homogeneous radiation response was observed in myxoid liposarcoma cell lines with SF2 between 0.64 and 0.67. Further comparing sarcomas of different origin, synovial sarcomas, as a group, showed the lowest SF2 values (mean 0.35) and was significantly more radiosensitive than myxoid liposarcomas and leiomyosarcomas (P = 0.0084 and 0.024, respectively). This study demonstrates a broad spectrum of radiosensitivities across STS cell lines and reveals subtype-specific radiation responses. The particular cellular radiosensitivity of synovial sarcoma cells supports consideration of the different sarcoma entities in clinical studies that aim to optimize sarcoma radiotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI